| Lipids Management |
1 |
1 |
| Type 2 Diabetes Mellitus |
0 |
0.9 |
| Glucocorticoid |
0 |
0.99 |
| Hypertension |
0 |
0.46 |
| Statins |
0 |
0.38 |
| Blood |
0 |
0.33 |
| Hyperglycemia |
0 |
0.33 |
| Antipsychotics |
0 |
0.28 |
| Heart Failure (HF) |
0 |
0.28 |
| Hypoglycemia |
0 |
0.28 |
| Cardiovascular Risk Management |
0 |
0.26 |
| Atypical Antipsychotics |
0 |
0.23 |
| Continuous Glucose Monitoring |
0 |
0.23 |
| Arrhythmia |
0 |
0.22 |
| Hypokalemia |
0 |
0.19 |
| Insulin Resistance |
0 |
0.19 |
| Coronary Artery Disease (CAD) |
0 |
0.17 |
| Myocardial Infarction (MI) |
0 |
0.16 |
| Corticosteroids |
0 |
0.14 |
| Diuretics |
0 |
0.14 |
| Patient Safety |
0 |
0.13 |
| Weight Management |
0 |
0.13 |
| Prostate Cancer |
0 |
0.12 |
| Biologic Therapy |
0 |
0.11 |
| Adverse Effects |
0 |
0.1 |
| Endocrinology |
0 |
0.1 |
| Heart |
0 |
0.1 |
| Insulin Therapy |
0 |
0.1 |
| Metabolism |
0 |
0.1 |
| Receptors |
0 |
0.1 |
| Steroids |
0 |
0.1 |
| Triglycerides |
0 |
0.1 |
| Weight Gain |
0 |
0.1 |
| Gonadotropin-Releasing Hormone (GnRH) Agonists |
0 |
0.08 |
| Tyrosine Kinase Inhibitor |
0 |
0.07 |